Pliant Therapeutics, Inc. (PLRX) Stock Forecast
PLRX analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 2.75 / 5 from 4 analysts
- Price target
- $2.00 average of analyst targets
- Upside to target
- +122.2% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.37
- 52-week range
- $0.88 – $1.87
PLRX analyst ratings
4 analystsNumber of analysts at each rating.
PLRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PLRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.37 | −$0.39 | −$0.36 | −$0.43 | +13.9% | 3 |
| Current fiscal year (2026) | −$1.43 | −$1.47 | −$1.41 | −$2.40 | +40.4% | 3 |
| Next fiscal year (2027) | −$1.28 | −$1.47 | −$0.94 | −$1.43 | +10.4% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PLRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 4 |
PLRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PLRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.36 | −$0.36 | −$0.36 | −$0.38 | −$0.37 | +1.6% | 0 up · 2 down |
| Current fiscal year (2026) | −$1.42 | −$1.41 | −$1.41 | −$1.46 | −$1.43 | +1.1% | 2 up · 2 down |
| Next fiscal year (2027) | −$1.03 | −$0.81 | −$0.81 | −$1.33 | −$1.28 | +25.3% | 2 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PLRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PLRX beat in 7 of 12.
What analysts expect from PLRX
4 analysts cover Pliant Therapeutics; their consensus rating is hold (2.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $2.00, 122.2% above the latest close of $0.90. Analysts expect earnings of −$1.43 per share for 2026, +40.4% from a year earlier. For 2027 the average estimate is −$1.28 per share. Pliant Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: PLRX income statement, PLRX key metrics, PLRX chart. See the PLRX stock overview for the latest quote and news.
PLRX forecast FAQ
What is Pliant Therapeutics's price target?
The average analyst price target for Pliant Therapeutics is $2.00, 122.2% above the latest close of $0.90.
Is Pliant Therapeutics a buy, hold or sell?
Of 4 analysts covering Pliant Therapeutics, 0 rate it a strong buy, 0 a buy, 3 a hold, 1 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Pliant Therapeutics's EPS forecast?
Analysts forecast −$1.43 per share for 2026 (range −$1.47 to −$1.41); for 2027 the estimate is −$1.28.
When does Pliant Therapeutics report earnings?
Pliant Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.37.
Does Pliant Therapeutics usually beat earnings estimates?
Pliant Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.